Drug shortages or anticipated problems with HIV medicine have not been identified.
The U.S. Food and Drug Administration (FDA) is closely monitoring the drug supply chain as the COVID-19 outbreak has the potential to disrupt the supply of medical and pharmaceutical products in the United States.
The National Alliance of State and Territorial AIDS Directors (NASTAD) has also remained in contact with the major manufacturers of HIV medicine as many of these products rely on ingredients produced in China.
As of March 10, 2020, there were no reports of manufacturing concerns or supply shortages.
Learn more about the FDA’s response to COVID-19external icon.